Harbour Investments Inc. Has $678,000 Holdings in Boston Scientific Corporation $BSX

Harbour Investments Inc. boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 17.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,308 shares of the medical equipment provider’s stock after purchasing an additional 929 shares during the quarter. Harbour Investments Inc.’s holdings in Boston Scientific were worth $678,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after purchasing an additional 1,664,108 shares in the last quarter. Swedbank AB raised its holdings in Boston Scientific by 114.5% in the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after purchasing an additional 1,505,019 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Finally, Ninety One UK Ltd grew its holdings in shares of Boston Scientific by 33.5% in the 2nd quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock valued at $552,755,000 after buying an additional 1,290,414 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on BSX shares. Truist Financial lifted their target price on Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Wells Fargo & Company lifted their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research note on Monday, September 29th. Raymond James Financial raised their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Finally, Barclays upped their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $120.71.

Insider Buying and Selling at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,214 shares of company stock valued at $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 1.5%

NYSE:BSX opened at $99.20 on Monday. The company has a market cap of $146.99 billion, a P/E ratio of 59.05, a price-to-earnings-growth ratio of 2.39 and a beta of 0.61. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The business has a 50 day moving average price of $101.29 and a two-hundred day moving average price of $101.77. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the firm posted $0.62 earnings per share. The firm’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.